JP2022525429A5 - - Google Patents
Info
- Publication number
- JP2022525429A5 JP2022525429A5 JP2021557650A JP2021557650A JP2022525429A5 JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5 JP 2021557650 A JP2021557650 A JP 2021557650A JP 2021557650 A JP2021557650 A JP 2021557650A JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- composition
- administered
- mol
- guide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021006A JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825676P | 2019-03-28 | 2019-03-28 | |
| US201962825637P | 2019-03-28 | 2019-03-28 | |
| US62/825,637 | 2019-03-28 | ||
| US62/825,676 | 2019-03-28 | ||
| PCT/US2020/025533 WO2020198706A1 (en) | 2019-03-28 | 2020-03-27 | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Division JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525429A JP2022525429A (ja) | 2022-05-13 |
| JP2022525429A5 true JP2022525429A5 (enExample) | 2023-12-15 |
| JP7636338B2 JP7636338B2 (ja) | 2025-02-26 |
Family
ID=70334147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557650A Active JP7636338B2 (ja) | 2019-03-28 | 2020-03-27 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230035659A1 (enExample) |
| EP (1) | EP3946285A1 (enExample) |
| JP (2) | JP7636338B2 (enExample) |
| KR (1) | KR20220004984A (enExample) |
| CN (1) | CN113874004A (enExample) |
| AU (1) | AU2020248337A1 (enExample) |
| CA (1) | CA3134544A1 (enExample) |
| CO (1) | CO2021014562A2 (enExample) |
| MX (1) | MX2021011690A (enExample) |
| WO (1) | WO2020198706A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| EP4259792A1 (en) * | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| EP4322920A1 (en) * | 2021-04-17 | 2024-02-21 | Intellia Therapeutics, Inc. | Lipid nanoparticle compositions |
| CA3220738A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| WO2022271780A1 (en) * | 2021-06-22 | 2022-12-29 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024003805A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Methods and compositions for ttr gene editing and therapy using crispr system |
| KR20260094824A (ko) * | 2023-10-25 | 2026-06-23 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 고효율, 저오프타겟 유전자 편집 도구 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| CA2754043A1 (en) * | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| PT2931898E (pt) * | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| KR20160097338A (ko) * | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도 |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018007871A1 (en) * | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
| WO2018067447A1 (en) | 2016-10-03 | 2018-04-12 | Itellia Therapeutics, Inc. | Improved methods for identifying double strand break sites |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| IL311278B2 (en) * | 2017-09-29 | 2026-05-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
| TWI904069B (zh) * | 2017-09-29 | 2025-11-11 | 美商英特利亞醫療公司 | 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法 |
-
2020
- 2020-03-27 MX MX2021011690A patent/MX2021011690A/es unknown
- 2020-03-27 JP JP2021557650A patent/JP7636338B2/ja active Active
- 2020-03-27 WO PCT/US2020/025533 patent/WO2020198706A1/en not_active Ceased
- 2020-03-27 CA CA3134544A patent/CA3134544A1/en active Pending
- 2020-03-27 KR KR1020217035012A patent/KR20220004984A/ko active Pending
- 2020-03-27 CN CN202080039394.5A patent/CN113874004A/zh active Pending
- 2020-03-27 AU AU2020248337A patent/AU2020248337A1/en active Pending
- 2020-03-27 EP EP20720676.4A patent/EP3946285A1/en active Pending
-
2021
- 2021-09-27 US US17/486,758 patent/US20230035659A1/en not_active Abandoned
- 2021-10-28 CO CONC2021/0014562A patent/CO2021014562A2/es unknown
-
2025
- 2025-02-12 JP JP2025021006A patent/JP2025081416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525428A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| EP3305302B1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
| JP2023103244A5 (enExample) | ||
| JP7829035B2 (ja) | アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法 | |
| GB2613457A (en) | Base editing of angptl3 and methods of using same for treatment of disease | |
| JP2023537943A5 (enExample) | ||
| US10208309B2 (en) | Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| HRP20180093T1 (hr) | Pripravci i postupci za inhibiciju ekspresije transtiretina | |
| HK1246648A1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| CA2320965A1 (en) | Methods and compounds for the genetic treatment of hyperlipidemia | |
| EP3349730B1 (en) | Systems for nucleic acid expression in vivo | |
| JP2010532163A5 (enExample) | ||
| JP2015518475A (ja) | 非アルコール性脂肪性肝炎の治療方法 | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| JP2024512635A5 (enExample) | ||
| JP2024543952A5 (enExample) | ||
| JP2023541170A (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| WO2003043663A1 (fr) | Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation | |
| EP4192477A1 (en) | Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk) | |
| JP2025515011A5 (enExample) | ||
| CN121335977A (zh) | 用于调节纤溶酶原激活物抑制剂-1(pai-1)的方法和组合物 | |
| US20210338835A1 (en) | Methods for treating subjects suffering from acute myeloid leukemia with flt3 ligand-targeted mir-150 nanoparticles |